

Draft

Obstructive sleep apnoea/ hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

Evidence review M: Demonstration of efficacy

NICE guideline

Intervention evidence review

March 2021

Draft for Consultation

Developed by the National Guideline Centre

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2021. All rights reserved. Subject to Notice of rights.

Contents

1	Demonstration of efficacy	5
1.1	Review question: How should efficacy of treatment be demonstrated?	5
1.2	Introduction	5
1.3	PICO table.....	5
1.4	Clinical evidence	6
1.4.1	Included studies	6
1.4.2	Summary of clinical studies included in the evidence review.....	6
1.4.3	Quality assessment of clinical studies included in the evidence review	6
1.5	Economic evidence	6
1.5.1	Included studies	6
1.5.2	Excluded studies.....	6
1.5.3	Health economic modelling	6
1.5.4	Health economic evidence statements.....	6
1.6	The committee’s discussion of the evidence.....	7
1.6.1	Interpreting the evidence.....	7
1.6.2	The outcomes that matter most.....	7
1.6.3	The quality of the evidence	7
1.6.4	Benefits and harms	7
	Appendices	15
	Appendix A: Review protocols	15
	Appendix B: Literature search strategies	22
	Appendix C: Clinical evidence selection.....	33
	Appendix D: Clinical evidence tables	34
	Appendix E: Forest Plots	34
	Appendix F: GRADE tables	34
	Appendix G: Health economic evidence selection	35
	Appendix H: Excluded studies.....	36

1 Demonstration of efficacy

1.1 Review question: How should efficacy of treatment be demonstrated?

1.2 Introduction

Having embarked on treatment for obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and COPD-OSAHS overlap syndrome, it is important to assess whether this is working or if further therapy modifications are required. There has not been a standardised approach to this, nor have there been national guidelines, so practice varies between centres. Some have had a symptom focussed approach to assessing treatment efficacy, others have performed repeat sleep studies, others have used data available from downloads of positive airway pressure therapy. Newer widely available CPAP machines and telemonitoring allow more data on overnight sleep disordered breathing to be collected and potentially easily reviewed.

1.3 PICO table

For full details see the review protocol in appendix A.

Table 1: PICO characteristics of review question

Population	<p>People being treated for OSAHS/OHS/ COPD-OSAHS overlap syndrome, stratified by:</p> <ul style="list-style-type: none"> • disease severity (mild vs moderate vs severe) • condition (OSAHS/OHS/ COPD-OSAHS overlap syndrome) • type of treatment (CPAP vs surgery vs positional modifiers vs oral devices)
Interventions	<ul style="list-style-type: none"> • using ESS (Epworth Sleepiness Scale) • using AHI (Apnoea Hypopnea Index) • using ODI (Oxygen desaturation index) • using SAQLI (Calgary Sleep Apnea Quality of Life Index) • using partner reported symptoms • using hours of use • using ABG based CO₂ monitoring (for OHS only) • using transcutaneous CO₂ monitoring (for OHS only) <p>Treatment to be adjusted during the period of measurements</p>
Comparisons	Any of the above vs any other in isolation or combination
Outcomes	<p>Critical</p> <ul style="list-style-type: none"> • generic or disease specific quality of life measures (continuous) • mortality (dichotomous) <p>Important</p> <ul style="list-style-type: none"> • sleepiness scores (continuous, e.g. Epworth) • apnoea-hypopnoea index (continuous) • oxygen desaturation index (continuous) • CO₂ control (continuous) • hours of use (adherence measure, continuous) • minor adverse effects of treatment (rates or dichotomous)

	<ul style="list-style-type: none">• driving outcomes (continuous)• neurocognitive outcomes (continuous)• impact on co-existing conditions:<ul style="list-style-type: none">○ HbA1c for diabetes (continuous)○ cardiovascular events for cardiovascular disease (dichotomous)○ systolic blood pressure for hypertension (continuous) <p>All follow-up times will be included. Follow-up times will be grouped as: follow-up ≤ 1 year and > 1 year</p>
Study design	<ul style="list-style-type: none">• RCTs <p>Minimum follow-up 1 month</p>

1 1.4 Clinical evidence

2 1.4.1 Included studies

3 A search was conducted for studies on markers/indices/ measures to monitor treatment in
4 patients with OSAHS/OHS/ COPD-OSAHS overlap syndrome. No relevant studies were
5 identified.

6 See the excluded studies list in appendix I.

7 1.4.2 Summary of clinical studies included in the evidence review

8 No studies included in the review.

9 1.4.3 Quality assessment of clinical studies included in the evidence review

10 No studies included in the review.

11 1.5 Economic evidence

12 1.5.1 Included studies

13 No health economic studies were included.

14 1.5.2 Excluded studies

15 No relevant health economic studies were excluded due to assessment of limited
16 applicability or methodological limitations.

17 See also the health economic study selection flow chart in appendix G.

18 1.5.3 Health economic modelling

19 Original modelling was not conducted for this question.

20 1.5.4 Health economic evidence statements

21 No relevant economic evaluations were identified.

22

1 **1.6 The committee's discussion of the evidence**

2 **1.6.1 Interpreting the evidence**

3 **1.6.1.1 The outcomes that matter most**

4 The committee considered the outcomes of health-related quality of life and mortality as
5 critical outcomes for decision making. Other important outcomes included sleepiness scores
6 (continuous, e.g. Epworth), apnoea-hypopnoea index, oxygen desaturation index, CO₂
7 control, hours of use (adherence measure), minor adverse effects of treatment, driving
8 outcomes, neurocognitive outcomes, impact on co-existing conditions, HbA1c for diabetes,
9 cardiovascular events for cardiovascular disease, systolic blood pressure for hypertension.

10 There was no evidence available for any of the outcomes.

11 **1.6.1.2 The quality of the evidence**

12 No evidence was available for this review question.

13 **1.6.2 Benefits and harms**

14 **OSAHS (CPAP, oral devices, positional modifiers)**

15 There was no evidence on demonstrating efficacy for treatments for people with OSAHS, so
16 the guideline committee made recommendations based on their experience and knowledge
17 of current best practice.

18 The committee discussed that an ideal measure of treatment efficacy would demonstrate
19 control of symptoms, control of AHI and uptake and adherence to therapy. The committee
20 noted that there was a huge variation in practice in the use of monitoring methods/measures.

21 The committee agreed that clinicians would want optimal control of symptoms after
22 treatment. The symptoms could be snoring, witnessed apnoea, unrefreshing sleep,
23 excessive sleepiness, nocturia, tiredness, insomnia, headaches, sleep fragmentation, ankle
24 swelling, and cognitive dysfunction/memory impairment. However, they agreed that
25 treatment efficacy cannot be decided on improvements of symptoms alone as it is an
26 imprecise indicator of treatment success and some may be symptom-free at the outset.

27 The committee discussed that objective measures such as AHI should be used to assess the
28 efficacy of CPAP/mandibular advancement splint /positional modifier treatment. The
29 committee did not want to prescribe a threshold for AHI but agreed that the aim of the
30 treatment is to achieve AHI <5. Committee members agreed that AHI<5 is the normal range,
31 but they did not come to a consensus as AHI <5 is not always achieved after treatment.

32 The committee discussed the use of patient reported and objective adherence measures to
33 assess efficacy of treatment. The committee noted that subjective reports of compliance
34 often result in over reporting of adherence and cannot be reliably used. They agreed that it is
35 responsibility of clinicians to use machine data and telemonitoring where available.

36 The committee stated that newer CPAP machines can track adherence, date ranges of use,
37 number of nights used and not used, percentage of nights with use, percentage of nights with
38 use ≥ 4 hours or < 4 hours, average use on all nights, apnoea-hypopnoea index (AHI) and
39 mask leak.

40 The committee identified several factors that commonly cause problems with CPAP that
41 should be routinely reviewed if treatment is not working.

1 The committee agreed that in people using CPAP their understanding and experience of
2 treatment should be explored, and mask fit/leak, cleaning and maintaining equipment, nasal
3 and mouth dryness, as well as other factors affecting sleep disturbance such as insomnia,
4 restless legs, sleep hygiene, shift work, sleep routines should be reviewed. Careful history
5 taking is required and further detailed investigation may be needed in some cases (for
6 example polysomnography, monitoring of limb movements, or actigraphy), particularly when
7 additional non-respiratory sleep disorders are suspected.

8 The committee noted that CPAP is just one aspect of the treatment for OSAHS, and that
9 monitoring should be tailored to the person's overall treatment plan, which may include
10 lifestyle changes and weight management, modifying sedative drugs and alcohol, stopping
11 smoking, and treating underlying lung disease and other comorbidities.

12 The committee discussed that reviewing symptoms as well as ESS, AHI and adherence to
13 therapy is current practice and implementation of these recommendations will not change
14 practice.

15 The committee agreed that if other therapies for OSAHS are used, such as customised
16 mandibular advancement splint, or positional modifiers then assessment of their
17 effectiveness should be measured once treatment has been optimised (e.g. after 3 months):
18 on symptoms including ESS, and AHI measured by repeat sleep study.

19 Even though there was a lack of evidence on demonstrating efficacy for treatments for
20 people with OSAHS, based on their experience the committee made strong
21 recommendations hence they did not make any research recommendation for this topic.

22

23 **OHS (non-invasive ventilation, CPAP)**

24 There was no evidence for demonstrating efficacy for treatments for OHS, so the guideline
25 committee made recommendations based on their experience and knowledge of current best
26 practice. In OHS control of hypoventilation is demonstrated by improvement of symptoms,
27 hypercapnia when awake and asleep, and oxygenation. It is important to optimise these in
28 order to improve well-being and prognosis, and to reduce the risk of hospital admission.

29 The committee agreed that clinical effectiveness of treatment (CPAP/non-invasive
30 ventilation) in people with OHS should be assessed by reviewing: symptoms of OSAHS and
31 hypoventilation including ESS, AHI, adherence to therapy, an assessment of improvement in
32 oxygenation and hypercapnia while awake and asleep and telemonitoring or download
33 information from CPAP or non-invasive ventilation device.

34 The committee agreed that in people using CPAP their understanding and experience of
35 treatment should be explored, and mask fit/leak, cleaning and maintenance of equipment,
36 nasal and mouth dryness, other factors affecting sleep disturbance such as insomnia,
37 restless legs, sleep hygiene, shift work, sleep routines should be reviewed.

38 The committee highlighted that in people with OHS, the need for oxygen therapy and
39 adherence to this should be reviewed after treatment with non-invasive ventilation or CPAP
40 has been optimised.

41 The committee noted that CPAP and non-invasive ventilation are just part the treatment for
42 OHS, and that monitoring should be tailored to the person's overall treatment plan, which
43 should also include lifestyle changes and weight management, modifying sedative drugs and
44 alcohol, stopping smoking, and treating underlying lung disease and other comorbidities. The
45 committee discussed that reviewing symptoms including ESS, AHI and adherence to therapy
46 is current practice and implementation of these recommendations will not change practice.

1 The committee highlighted that in people with OHS, non-invasive ventilation or CPAP should
2 be optimised first before reviewing requirement for long term oxygen therapy.

3 Even though there was a lack of evidence on demonstrating efficacy for treatments for
4 people with OHS, based on their experience the committee made strong recommendations
5 hence they did not make any research recommendation for this topic.

7 **COPD-OSAHs overlap syndrome (non-invasive ventilation, CPAP, oxygen therapy)**

8 COPD-OSAHs overlap syndrome is defined by the presence of COPD and OSAHS.
9 Treatment for overlap syndrome is to address underlying COPD, OSA, or both.

10 There was no evidence for demonstrating efficacy for treatments for COPD-OSAHs overlap
11 syndrome, so the guideline committee made recommendations based on their experience
12 and knowledge of current best practice.

13 In COPD-OSAHs overlap syndrome, control of hypoventilation is demonstrated by
14 improvement of daytime and night time oxygenation and hypercapnia; this is important to
15 improve prognosis.

16 The committee agreed that clinical effectiveness of treatment (CPAP/non-invasive
17 ventilation) in people with COPD-OSAHs overlap syndrome should be assessed by
18 reviewing: symptoms of OSAHS and hypoventilation including ESS, AHI, adherence to
19 therapy, improvement in oxygenation and hypercapnia (if present) while awake and asleep ,
20 if present and telemonitoring or download information from CPAP or non-invasive ventilation
21 device.

22 The committee agreed that in people using CPAP their understanding and experience of
23 treatment should be explored, and mask fit/leak, nasal and mouth dryness, other factors
24 affecting sleep disturbance such as insomnia, restless legs, sleep hygiene, shift work, sleep
25 routines should be reviewed. They noted that sleep quality may be poor in COPD patients,
26 with disruption from cough, wheeze, restless legs and medication.

27 In some patients with severe COPD and COPD-OSAHs overlap syndrome optimised
28 treatment of the OSAHS may produce an objective improvement in indices such as the AHI
29 or oxygen desaturation during sleep but fail to improve symptoms or quality of life for the
30 patient. This would usually be because the severity of the person's COPD has the over-riding
31 influence on quality of life. Since use of non-invasive ventilation or CPAP equipment adds to
32 the burden of therapy, consideration should be given to the stopping these and using a
33 symptom management approach. This requires careful discussion with the patient and their
34 care givers, may also include discussions care planning (for example COPD exacerbation
35 action plan and advance care planning) for those with severe COPD. The committee
36 discussed that reviewing symptoms/sleepiness and adherence to therapy is current practice
37 and implementation of these recommendations will not change practice.

38 The committee highlighted that in people with COPD-OSAHs overlap syndrome who are
39 already having supplemental oxygen therapy, the need for oxygen therapy should be
40 reviewed after treatment with non-invasive ventilation or CPAP has been optimised. Effective
41 treatment with CPAP or non-invasive ventilation may improve the person's condition to the
42 extent that they no longer fulfil the criteria for supplemental oxygen.

43 Even though there was a lack of evidence on demonstrating efficacy for treatments for
44 people with COPD-OSAHs overlap syndrome, based on their experience the committee
45 made strong recommendations hence they did not make any research recommendation for
46 this topic.

1 **1.6.3 Cost effectiveness and resource use**

2 There were no economic or clinical evaluations identified for this review question. The
3 committee therefore made consensus recommendations based on current practice.

4 Since treatments in these conditions are potentially for life it is important for cost
5 effectiveness as well as for patient welfare to assess whether a treatment is working and
6 then, if necessary, to modify or discontinue treatment.

7 The committee recommended assessing symptom control and, especially for CPAP and non-
8 invasive ventilation factors that affect adherence. These assessments are already current
9 practice. The frequency of monitoring is discussed in evidence report L.

10 Although control of symptoms is important, the committee agreed that treatment efficacy
11 cannot be decided on improvements of symptoms alone as they are an imprecise indicator of
12 treatment success and some people may be symptom-free at the outset. Therefore, they
13 recommended the re-assessment of severity of OSAHS using AHI. For patients being treated
14 with CPAP or non-invasive ventilation this is downloaded from the device itself and can be
15 done remotely where there is telemonitoring – see Chapter L. However, for patients receiving
16 other treatments this might require a home or hospital sleep study. For patients with OHS or
17 overlap syndrome an assessment of improvement in oxygenation and hypercapnia would
18 also be required.

References

1. Ahmed O, Parthasarathy S. APAP and alternative titration methods. *Sleep Medicine Clinics*. 2010; 5(3):361-368
2. Alvarez RF, Rabec C, Rubinos Cuadrado G, Cascon Hernandez JA, Rodriguez P, Georges M et al. Monitoring noninvasive ventilation in patients with obesity hypoventilation syndrome: Comparison between ventilator built-in software and respiratory polygraphy. *Respiration*. 2017; 93(3):162-169
3. Arya D, Singh SV, Tripathi A, Tripathi SK. A pilot study to compare patient perception of obstructive sleep apnea treatment with CPAP or appliance therapy. *Journal of Prosthetic Dentistry*. 2014; 112(5):1188-1193
4. Baessler A, Nadeem R, Harvey M, Madbouly E, Younus A, Sajid H et al. Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers - a meta-analysis. *Journal of Inflammation*. 2013; 10:13
5. Baltaxe E, Embid C, Aumatell E, Martinez M, Barberan-Garcia A, Kelly J et al. Integrated care intervention supported by a mobile health tool for patients using noninvasive ventilation at home: Randomized controlled trial. *JMIR MHealth and UHealth*. 2020; 8(4):e16395
6. Berg LM, Ankjell TKS, Sun YQ, Trovik TA, Sjögren A, Rikardsen OG et al. Friedman score in relation to compliance and treatment response in nonsevere obstructive sleep apnea. *International Journal of Otolaryngology*. 2020; 2020:6459276
7. Bergeron M, Duggins AL, Cohen AP, Tiemeyer K, Mullen L, Crisalli J et al. A shared decision-making tool for obstructive sleep apnea without tonsillar hypertrophy: A randomized controlled trial. *Laryngoscope*. 2018; 128(4):1007-1015
8. Brostrom A, Pakpour AH, Nilssen P, Hedberg B, Ulander M. Validation of CollaboRATE and SURE - two short questionnaires to measure shared decision making during CPAP initiation. *Journal of Sleep Research*. 2018; 28(5):e12808
9. Budhiraja R, Kushida CA, Nichols DA, Walsh JK, Simon RD, Gottlieb DJ et al. Predictors of sleepiness in obstructive sleep apnoea at baseline and after 6 months of continuous positive airway pressure therapy. *European Respiratory Journal*. 2017; 50(5):11
10. Caminero AB, Pareja JA, Millán I, de Pablos MJ. "Tailored" polysomnography: an alternative method in the assessment of obstructive sleep apnea syndrome. *Neurologia*. 1997; 12(7):281-286
11. Carrera M, Barbe F, Agusti AGN. Does the number of hypopnoeas influence therapy in patients with obstructive sleep apnoea? *Respiratory Medicine*. 1998; 92(8):1028-1031
12. Choi JH, Cho SH, Kim SN, Suh JD, Cho JH. Predicting outcomes after uvulopalatopharyngoplasty for adult obstructive sleep apnea: A meta-analysis. *Otolaryngology - Head & Neck Surgery*. 2016; 155(6):904-913
13. Choi S, Bennett LS, Mullins R, Davies RJ, Stradling JR. Which derivative from overnight oximetry best predicts symptomatic response to nasal continuous positive airway pressure in patients with obstructive sleep apnoea? *Respiratory Medicine*. 2000; 94(9):895-899

- 1 14. Choi S, Mullins R, Crosby JH, Davies RJ, Stradling JR. Is (re)titration of nasal
2 continuous positive airway pressure for obstructive sleep apnoea necessary? *Sleep*
3 *Medicine*. 2001; 2(5):431-435
- 4 15. Damiani MF, Quaranta VN, Tedeschi E, Drigo R, Ranieri T, Carratu P et al. Titration
5 effectiveness of two autoadjustable continuous positive airway pressure devices
6 driven by different algorithms in patients with obstructive sleep apnoea. *Respirology*.
7 2013; 18(6):968-973
- 8 16. Deng ZH, Li JR, Hou Q, Chen NN, Cui ZY, Li LZ et al. [Role of sleep apnea
9 monitoring management platform in the treatment of patients with obstructive sleep
10 apnea hypopnea syndrome]. *Journal of Clinical Otorhinolaryngology, Head, and Neck*
11 *Surgery*. 2017; 31(21):1646-1648;1652
- 12 17. Ebben MR, Narizhnaya M, Krieger AC. A new predictive model for continuous
13 positive airway pressure in the treatment of obstructive sleep apnea. *Sleep &*
14 *Breathing*. 2017; 21(2):435-442
- 15 18. Georges M, Adler D, Contal O, Espa F, Pépin JL, Janssens JP. Reliability of the
16 apnoea-hypopnoea index (AHI) reported by ventilator software in patients with
17 obesity hypoventilation syndrome (OHS) treated with long-term noninvasive
18 ventilation (NIV). *European Respiratory Journal*. 2013; 42(Suppl 57):p2466
- 19 19. Georges M, Adler D, Contal O, Espa F, Perrig S, Pepin JL et al. Reliability of apnea-
20 hypopnea index measured by a home bi-level pressure support ventilator versus a
21 polysomnographic assessment. *Respiratory Care*. 2015; 60(7):1051-1056
- 22 20. Inoue Y, Miki M, Tabata T. Findings of the Maintenance of Wakefulness Test and its
23 relationship with response to modafinil therapy for residual excessive daytime
24 sleepiness in obstructive sleep apnea patients adequately treated with nasal
25 continuous positive airway pressure. *Sleep Medicine*. 2016; 27-28:45-48
- 26 21. Javaheri S, Gottlieb DJ, Quan SF. Effects of continuous positive airway pressure on
27 blood pressure in obstructive sleep apnea patients: The Apnea Positive Pressure
28 Long-term Efficacy Study (APPLES). *Journal of Sleep Research*. 2020; 29(2):e12943
- 29 22. Jonas DE, Amick HR, Feltner C, Weber RP, Arvanitis M, Stine A et al. Screening for
30 obstructive sleep apnea in adults: An evidence review for the U.S. Preventive
31 Services Task Force. Evidence synthesis no. 146. Rockville, MD. Agency for
32 Healthcare Research and Quality (US), 2017. Available from:
33 https://www.ncbi.nlm.nih.gov/books/NBK424160/pdf/Bookshelf_NBK424160.pdf
- 34 23. Kunisaki KM, Khalil W, Koffel E, Pfannes L, Koeller E, MacDonald R et al. The
35 comparative effectiveness, harms, and cost of care models for the evaluation and
36 treatment of obstructive sleep apnea (OSA): a systematic review. Washington (DC).
37 Department of Veterans Affairs (US), 2016. Available from:
38 <https://www.hsrd.research.va.gov/publications/esp/SleepApnea.pdf>
- 39 24. Lee GH, Kim MJ, Lee EM, Kim CS, Lee SA. Prediction of optimal CPAP pressure and
40 validation of an equation for Asian patients with obstructive sleep apnea. *Respiratory*
41 *Care*. 2013; 58(5):810-815
- 42 25. Leger D, Elbaz M, Piednoir B, Carron A, Texereau J. Evaluation of the add-on
43 NOWAPI medical device for remote monitoring of compliance to Continuous Positive
44 Airway Pressure and treatment efficacy in obstructive sleep apnea. *Biomedical*
45 *Engineering Online*. 2016; 15:26
- 46 26. Masa JF, Corral J, Pereira R, Duran-Cantolla J, Cabello M, Hernandez-Blasco L et al.
47 Therapeutic decision-making for sleep apnea and hypopnea syndrome using home

- 1 respiratory polygraphy: A large multicentric study. *American Journal of Respiratory*
2 *and Critical Care Medicine*. 2011; 184(8):964-971
- 3 27. Masa JF, Corral J, Romero A, Caballero C, Teran-Santos J, Alonso-Alvarez ML et al.
4 The effect of supplemental oxygen in obesity hypoventilation syndrome. *Journal of*
5 *Clinical Sleep Medicine*. 2016; 12(10):1379-1388
- 6 28. Masa JF, Corral J, Sanchez de Cos J, Duran-Cantolla J, Cabello M, Hernandez-
7 Blasco L et al. Effectiveness of three sleep apnea management alternatives. *Sleep*.
8 2013; 36(12):1799-1807
- 9 29. Masa JF, Mokhlesi B, Benitez I, Gomez de Terreros FJ, Sanchez-Quiroga MA,
10 Romero A et al. Long-term clinical effectiveness of continuous positive airway
11 pressure therapy versus non-invasive ventilation therapy in patients with obesity
12 hypoventilation syndrome: A multicentre, open-label, randomised controlled trial.
13 *Lancet*. 2019; 393(10182):1721-1732
- 14 30. Masdeu MJ, Ayappa I, Hwang D, Mooney AM, Rapoport DM. Impact of clinical
15 assessment on use of data from unattended limited monitoring as opposed to full-in
16 lab PSG in sleep disordered breathing. *Journal of Clinical Sleep Medicine*. 2010;
17 6(1):51-58
- 18 31. McArdle N, King S, Shepherd K, Baker V, Ramanan D, Ketheeswaran S et al. Study
19 of a novel APAP algorithm for the treatment of obstructive sleep apnea in women.
20 *Sleep*. 2015; 38(11):1775-1781
- 21 32. Mulgrew AT, Fox N, Ayas NT, Ryan CF. Diagnosis and initial management of
22 obstructive sleep apnea without polysomnography: a randomized validation study.
23 *Annals of Internal Medicine*. 2007; 146(3):157-166
- 24 33. Nannapaneni S, Morgenthaler TI, Ramar K. Assessing and predicting the likelihood of
25 interventions during routine annual follow-up visits for management of obstructive
26 sleep. *Journal of Clinical Sleep Medicine*. 2014; 10(8):919-924
- 27 34. National Institute for Health and Care Excellence. Developing NICE guidelines: the
28 manual [Updated 2018]. London. National Institute for Health and Care Excellence,
29 2014. Available from:
30 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 31 35. Ng SS, Tam W, Chan TO, To KW, Ngai J, Chan KKP et al. Use of Berlin
32 questionnaire in comparison to polysomnography and home sleep study in patients
33 with obstructive sleep apnea. *Respiratory Research*. 2019; 20(1):40
- 34 36. Papadakis CE, Chaidas K, Chimona TS, Asimakopoulou P, Ladias A, Proimos EK et
35 al. Use of oximetry to determine need for adenotonsillectomy for sleep-disordered
36 breathing. *Pediatrics*. 2018; 142(3):e20173382
- 37 37. Patout M, Arbane G, Cuvelier A, Muir JF, Hart N, Murphy PB. Polysomnography
38 versus limited respiratory monitoring and nurse-led titration to optimise non-invasive
39 ventilation set-up: a pilot randomised clinical trial. *Thorax*. 2019; 74(1):83-86
- 40 38. Pilz K, Thalhofer S, Meissner P, Dorow P. Improvement of CPAP Therapy by a Self-
41 Adjusting System. *Sleep & Breathing*. 2000; 4(4):169-172
- 42 39. Quintas-Neves M, Preto J, Drummond M. Assessment of bariatric surgery efficacy on
43 Obstructive Sleep Apnea (OSA). *Revista Portuguesa de Pneumologia*. 2016;
44 22(6):331-336

- 1 40. Rodrigues Thuler E, Silveira Dibern R, Fomin DS, De Oliveira JAA. Laser-assisted
2 uvulopalatoplasty - Comparative analisys of the clinical improvement and the
3 indication criteria. *Revista Brasileira de Otorrinolaringologia*. 2002; 68(2):190-193
- 4 41. Rosen CL, Auckley D, Benca R, Foldvary-Schaefer N, Iber C, Kapur V et al. A
5 multisite randomized trial of portable sleep studies and positive airway pressure
6 autotitration versus laboratory-based polysomnography for the diagnosis and
7 treatment of obstructive sleep apnea: The HomePAP study. *Sleep*. 2012; 35(6):757-
8 767
- 9 42. Rosen CL, Wang R, Taylor HG, Marcus CL, Katz ES, Paruthi S et al. Utility of
10 symptoms to predict treatment outcomes in obstructive sleep apnea syndrome.
11 *Pediatrics*. 2015; 135(3):e662-671
- 12 43. Sanchez-Quiroga MA, Corral J, Gomez-de-Terreros FJ, Carmona-Bernal C, Asensio-
13 Cruz MI, Cabello M et al. Primary care physicians can comprehensively manage
14 sleep apnea patients: A non-inferiority randomized controlled trial. *American Journal of
15 Respiratory and Critical Care Medicine*. 2018; 198(5):648-656
- 16 44. Saur JS, Brietzke SE. Polysomnography results versus clinical factors to predict post-
17 operative respiratory complications following pediatric adenotonsillectomy.
18 *International Journal of Pediatric Otorhinolaryngology*. 2017; 98:136-142
- 19 45. Schobel C, Knorre S, Glos M, Garcia C, Fietze I, Penzel T. Improved follow-up by
20 peripheral arterial tonometry in CPAP-treated patients with obstructive sleep apnea
21 and persistent excessive daytime sleepiness. *Sleep & Breathing*. 2018; 22(4):1153-
22 1160
- 23 46. Suen C, Ryan CM, Mubashir T, Ayas NT, Abrahamyan L, Wong J et al. Sleep study
24 and oximetry parameters for predicting postoperative complications in patients with
25 OSA. *Chest*. 2019; 155(4):855-867
- 26 47. Sutherland K, Phillips CL, Davies A, Srinivasan VK, Dalci O, Yee BJ et al. CPAP
27 pressure for prediction of oral appliance treatment response in obstructive sleep
28 apnea. *Journal of Clinical Sleep Medicine*. 2014; 10(9):943-949
- 29 48. Suzuki M, Saigusa H, Kurogi R, Morita S, Ishizuka Y. Postoperative monitoring of
30 esophageal pressure in patients with obstructive sleep apnea-hypopnea syndrome
31 who have undergone tonsillectomy with uvulopalatopharyngoplasty. *Annals of
32 Otology, Rhinology and Laryngology*. 2008; 117(11):849-853
- 33 49. Tam S, Woodson BT, Rotenberg B. Outcome measurements in obstructive sleep
34 apnea: beyond the apnea-hypopnea index. *Laryngoscope*. 2014; 124(1):337-343
- 35 50. Tedeschi E, Carratu P, Damiani MF, Ventura VA, Drigo R, Enzo E et al. Home
36 unattended portable monitoring and automatic CPAP titration in patients with high risk
37 for moderate to severe obstructive sleep apnea. *Respiratory Care*. 2013; 58(7):1178-
38 1183
- 39 51. Trikalinos TA, Ip S, Raman G, Cepeda MS, Balk EM, D'Ambrosio C et al. Home
40 diagnosis of obstructive sleep apnea-hypopnea syndrome. Rockville, MD. Agency for
41 Healthcare Research and Quality (US), 2007. Available from:
42 https://www.ncbi.nlm.nih.gov/books/NBK254138/pdf/Bookshelf_NBK254138.pdf

43
44
45

1 **Appendices**
2 **Appendix A: Review protocols**

3 **Table 2: Review protocol: demonstration of efficacy**

Field	Content
PROSPERO registration number	Not registered
Review title	Demonstration of efficacy
Review question	How should efficacy of treatment be demonstrated (for example, variable positive pressure titration device, oximetry, capnography or polysomnography titration)?
Objective	Determine the most clinically and cost-effective marker/index/ measure to monitor treatment in patients with OSAHS/OHS/COPD-OSAHS overlap syndrome.
Searches	<p>The following databases (from inception) will be searched:</p> <ul style="list-style-type: none"> • Cochrane Central Register of Controlled Trials (CENTRAL) • Cochrane Database of Systematic Reviews (CDSR) • Embase • MEDLINE • Epistemonikos <p>The searches may be re-run 6 weeks before the final committee meeting and further studies retrieved for inclusion if relevant.</p> <p>The full search strategies will be published in the final review.</p>
Condition or domain being studied	Obstructive sleep apnoea/hypopnoea syndrome is the most common form of sleep disordered breathing. The guideline will also cover obesity hypoventilation syndrome and COPD-OSAHS overlap syndrome (the coexistence of obstructive sleep apnoea/hypopnoea syndrome and chronic obstructive pulmonary disease).
Population	<p>Inclusion:</p> <p>People being treated for OSAHS/OHS/ COPD-OSAHS overlap syndrome, stratified by:</p> <ul style="list-style-type: none"> • Disease severity (mild vs moderate vs severe) • Condition (OSAHS/OHS/ COPD-OSAHS overlap syndrome) • Type of treatment (CPAP vs surgery vs positional modifiers vs oral devices) <p>Severity:</p> <ul style="list-style-type: none"> • Mild OSAHS: AHI >5 but <15 • Moderate OSAHS: AHI >= 15 but <30 • Severe OSAHS: AHI >= 30 <p>When a mixed severity population is included the severity of the majority of the population will be used by taking the mean AHI of the patients included and the study will be downgraded for indirectness.</p>

Intervention/Exposure/Test	<ul style="list-style-type: none"> • Using ESS (Epworth Sleepiness Scale) • Using AHI (Apnoea Hypopnea Index) • Using ODI (Oxygen desaturation index) • Using SAQLI (Calgary Sleep Apnea Quality of Life Index) • Using partner reported symptoms • Using hours of use • Using ABG based CO₂ monitoring (for OHS only) • Using transcutaneous CO₂ monitoring (for OHS only) <p>Treatment to be adjusted during the period of measurements</p>
Comparator/Reference standard/Confounding factors	Any of the above vs any other in isolation or combination
Types of study to be included	<ul style="list-style-type: none"> • RCTs <p>Minimum follow-up 1 month</p>
Other exclusion criteria	<p>Non-English language studies.</p> <p>Conference abstracts</p>
Context	-
Primary outcomes (critical outcomes)	<ul style="list-style-type: none"> • Generic or disease specific quality of life measures (continuous) • Mortality (dichotomous) <p>All follow-up times will be included. Follow-up times will be grouped as: follow-up \leq1 year and $>$1 year</p>
Secondary outcomes (important outcomes)	<ul style="list-style-type: none"> • Sleepiness scores (continuous, e.g. Epworth) • Apnoea-Hypopnoea index (continuous) • Oxygen desaturation index (continuous) • CO₂ control (continuous) • Hours of use (adherence measure, continuous) • Minor adverse effects of treatment (rates or dichotomous) • Driving outcomes (continuous) • Neurocognitive outcomes (continuous) • Impact on co-existing conditions: <ul style="list-style-type: none"> ○ HbA1c for diabetes (continuous) ○ Cardiovascular events for cardiovascular disease (dichotomous) ○ Systolic blood pressure for hypertension (continuous) <p>All follow-up times will be included. Follow-up times will be grouped as: follow-up \leq1 year and $>$1 year</p>
Data extraction (selection and coding)	<p>EndNote will be used for reference management, sifting, citations and bibliographies. All references identified by the searches and from other sources will be screened for inclusion. 10% of the abstracts will be reviewed by two reviewers, with any disagreements resolved by discussion or, if necessary, a third independent reviewer. The full text of potentially eligible studies will be retrieved and will be assessed in line with the criteria outlined above.</p> <p>EvIBASE will be used for data extraction.</p>

<p>Risk of bias (quality) assessment</p>	<p>Risk of bias will be assessed using the appropriate checklist as described in Developing NICE guidelines: the manual.</p> <ul style="list-style-type: none"> • Systematic reviews: Risk of Bias in Systematic Reviews (ROBIS) • Randomised Controlled Trial: Cochrane RoB (2.0) <p>10% of all evidence reviews are quality assured by a senior research fellow. This includes checking:</p> <ul style="list-style-type: none"> • papers were included /excluded appropriately • a sample of the data extractions • correct methods are used to synthesise data • a sample of the risk of bias assessments <p>Disagreements between the review authors over the risk of bias in particular studies will be resolved by discussion, with involvement of a third review author where necessary.</p>
<p>Strategy for data synthesis</p>	<p>Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).</p> <ul style="list-style-type: none"> • GRADEpro will be used to assess the quality of evidence for each outcome, taking into account individual study quality and the meta-analysis results. The 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision) will be appraised for each outcome. Publication bias is tested for when there are more than 5 studies for an outcome. <p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group http://www.gradeworkinggroup.org/</p> <p>Where meta-analysis is not possible, data will be presented and quality assessed individually per outcome.</p> <ul style="list-style-type: none"> • WinBUGS will be used for network meta-analysis, if possible given the data identified. <p>Heterogeneity between the studies in effect measures will be assessed using the I² statistic and visually inspected. An I² value greater than 50% will be considered indicative of substantial heterogeneity. Sensitivity analyses will be conducted based on pre-specified subgroups using stratified meta-analysis to explore the heterogeneity in effect estimates. If this does not explain the heterogeneity, the results will be presented pooled using random-effects.</p>
<p>Analysis of sub-groups</p>	<p>Subgroups that will be investigated if heterogeneity is present:</p> <ul style="list-style-type: none"> • High risk occupational groups (for example heavy goods vehicle drivers) vs general population • Sleepiness – Epworth >9 vs Epworth 9 or less • Coexisting conditions – type 2 diabetes vs atrial fibrillation vs hypertension vs none • BMI – obese vs non-obese

Type and method of review	<input checked="" type="checkbox"/>	Intervention
	<input type="checkbox"/>	Diagnostic
	<input type="checkbox"/>	Prognostic
	<input type="checkbox"/>	Qualitative
	<input type="checkbox"/>	Epidemiologic
	<input type="checkbox"/>	Service Delivery
	<input type="checkbox"/>	Other (please specify)
Language	English	
Country	England	
Anticipated or actual start date	NA – not registered on PROSPERO	
Anticipated completion date	NA – not registered on PROSPERO	
Named contact	<p>5a. Named contact National Guideline Centre</p> <p>5b Named contact e-mail SleepApnoHypo@nice.org.uk</p> <p>5e Organisational affiliation of the review National Institute for Health and Care Excellence (NICE) and the National Guideline Centre</p>	
Review team members	<p>From the National Guideline Centre:</p> <p>Carlos Sharpin, Guideline lead</p> <p>Sharangini Rajesh, Senior systematic reviewer</p> <p>Audrius Stonkus, Systematic reviewer</p> <p>Emtiyaz Chowdhury (until January 2020), Health economist</p> <p>David Wonderling, Head of health economics</p> <p>Agnes Cuyas, Information specialist (till December 2019)</p> <p>Jill Cobb, Information specialist</p>	
Funding sources/sponsor	This systematic review is being completed by the National Guideline Centre which receives funding from NICE.	
Conflicts of interest	<p>All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.</p>	

Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual . Members of the guideline committee are available on the NICE website: https://www.nice.org.uk/guidance/indevelopment/gid-ng10098
Other registration details	NA – not registered
Reference/URL for published protocol	NA – not registered
Dissemination plans	NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as: <ul style="list-style-type: none"> • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts • issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.
Keywords	-
Details of existing review of same topic by same authors	NA
Additional information	-
Details of final publication	www.nice.org.uk

1
2
3

Table 3: Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
Review strategy	Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.

Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).³⁴

Inclusion and exclusion criteria

- If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.
- If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will usually be excluded from the guideline. If it is excluded, then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.
- If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included.

Where there is discretion

The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2003 or later but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as 'Not applicable'.
- Studies published before 2003 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

1

Appendix B: Literature search strategies

Sleep Apnoea search strategy 2 demonstration of efficacy

This literature search strategy was used for the following review;

- How should efficacy of treatment be demonstrated (for example, variable positive pressure titration device, oximetry, capnography or polysomnography titration)?

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.³⁴

For more information, please see the Methods Report published as part of the accompanying documents for this guideline.

B.1 Clinical search literature search strategy

Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

Table 4: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 6 July 2020	Exclusions Randomised controlled trials Systematic review studies Observational studies
Embase (OVID)	1974 – 6 July 2020	Exclusions Randomised controlled trials Systematic review studies Observational studies
The Cochrane Library (Wiley)	Cochrane Reviews to 2020 Issue 7 of 12 CENTRAL to 2020 Issue 7 of 12	None
Epistemonikos (Epistemonikos Foundation)	Inception – 29 November 2018	None

Medline (Ovid) search terms

1.	exp Sleep Apnea Syndromes/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHS or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter/

<Click this field on the first page and insert footer text if required>

© NICE 2021. All rights reserved. Subject to Notice of rights.

10.	editorial/
11.	news/
12.	exp historical article/
13.	Anecdotes as Topic/
14.	comment/
15.	case report/
16.	(letter or comment*).ti.
17.	or/9-16
18.	randomized controlled trial/ or random*.ti,ab.
19.	17 not 18
20.	animals/ not humans/
21.	exp Animals, Laboratory/
22.	exp Animal Experimentation/
23.	exp Models, Animal/
24.	exp Rodentia/
25.	(rat or rats or mouse or mice).ti.
26.	or/19-25
27.	8 not 26
28.	(sleep* adj3 (tool* or index* or indic* or score* or scoring or scale*)).ti,ab.
29.	((spouse* or wife or wives or husband* or significant other* or partner* or family or families or care giver* or caregiver* or carer* or symptom*) adj (report* or observ* or watch* or note* or noting or hear* or listen*)).ti,ab.
30.	(out of hours or off hours).ti,ab.
31.	exp oximetry/ or capnography/ or polysomnography/
32.	(oximetry or capnogra* or capnometer or polysomnograph* or colorimetr* or conductometr* or potentiometr*).ti,ab.
33.	((carbon dioxide or CO2 or oxygen or O2) adj2 (monitor* or continuous*)).ti,ab.
34.	(blood gas adj2 (monitor* or continuous or test*)).ti,ab.
35.	Epworth Sleepiness Scale.ti,ab.
36.	Apnoea Hypopnea Index.ti,ab.
37.	Oxygen desaturation index.ti,ab.
38.	Calgary Sleep Apnea Quality of Life Index.ti,ab.
39.	(ESS or AHI or ODI or SQALI or ABG).ti,ab.
40.	or/28-39
41.	27 and 40
42.	Meta-Analysis/
43.	exp Meta-Analysis as Topic/
44.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
45.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
46.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
47.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
48.	(search* adj4 literature).ab.
49.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
50.	cochrane.jw.

51.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
52.	or/42-51
53.	randomized controlled trial.pt.
54.	controlled clinical trial.pt.
55.	randomi#ed.ti,ab.
56.	placebo.ab.
57.	randomly.ti,ab.
58.	Clinical Trials as topic.sh.
59.	trial.ti.
60.	or/53-59
61.	Epidemiologic studies/
62.	Observational study/
63.	exp Cohort studies/
64.	(cohort adj (study or studies or analys* or data)).ti,ab.
65.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
66.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
67.	Controlled Before-After Studies/
68.	Historically Controlled Study/
69.	Interrupted Time Series Analysis/
70.	(before adj2 after adj2 (study or studies or data)).ti,ab.
71.	exp case control study/
72.	case control*.ti,ab.
73.	Cross-sectional studies/
74.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
75.	or/61-74
76.	41 and (52 or 60 or 75)

1

Embase (Ovid) search terms

1.	exp Sleep Disordered Breathing/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHs or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter.pt. or letter/
10.	note.pt.
11.	editorial.pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.
14.	or/9-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15

17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/
20.	exp Experimental Animal/
21.	animal model/
22.	exp Rodent/
23.	(rat or rats or mouse or mice).ti.
24.	or/16-23
25.	8 not 24
26.	(sleep* adj3 (tool* or index* or indic* or score* or scoring or scale*)).ti,ab.
27.	((spouse* or wife or wives or husband* or significant other* or partner* or family or families or care giver* or caregiver* or carer* or symptom*) adj (report* or observ* or watch* or note* or noting or hear* or listen*)).ti,ab.
28.	(out of hours or off hours).ti,ab.
29.	exp oximetry/ or exp capnometry/ or capnometer/ or polysomnography/
30.	(oximetry or capnogra* or capnometer or polysomnograph* or colorimetr* or conductometr* or potentiometr*).ti,ab.
31.	((carbon dioxide or CO2 or oxygen or O2) adj2 (monitor* or continuous*)).ti,ab.
32.	(blood gas adj2 (monitor* or continuous or test*)).ti,ab.
33.	Epworth Sleepiness Scale.ti,ab.
34.	Apnoea Hypopnea Index.ti,ab.
35.	Oxygen desaturation index.ti,ab.
36.	Calgary Sleep Apnea Quality of Life Index.ti,ab.
37.	(ESS or AHI or ODI or SQALI or ABG).ti,ab.
38.	or/26-37
39.	25 and 38
40.	systematic review/
41.	meta-analysis/
42.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
43.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
44.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
45.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
46.	(search* adj4 literature).ab.
47.	(medline or pubmed or cochrane or embase or psychlit or psychlit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
48.	cochrane.jw.
49.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
50.	or/40-49
51.	random*.ti,ab.
52.	factorial*.ti,ab.
53.	(crossover* or cross over*).ti,ab.
54.	((doubl* or singl*) adj blind*).ti,ab.
55.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
56.	crossover procedure/
57.	single blind procedure/

58.	randomized controlled trial/
59.	double blind procedure/
60.	or/51-59
61.	Clinical study/
62.	Observational study/
63.	family study/
64.	longitudinal study/
65.	retrospective study/
66.	prospective study/
67.	cohort analysis/
68.	follow-up/
69.	cohort*.ti,ab.
70.	68 and 69
71.	(cohort adj (study or studies or analys* or data)).ti,ab.
72.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
73.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
74.	(before adj2 after adj2 (study or studies or data)).ti,ab.
75.	or/61-67,70-74
76.	exp case control study/
77.	case control*.ti,ab.
78.	cross-sectional study/
79.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
80.	or/75-79
81.	39 and (50 or 60 or 80)

1

Cochrane Library (Wiley) search terms

#1.	MeSH descriptor: [Sleep Apnea Syndromes] explode all trees
#2.	(sleep* near/4 (apnea* or apnoea* or hypopnea* or hypopnoea*)):ti,ab
#3.	(sleep* near/4 disorder* near/4 breath*):ti,ab
#4.	(OSAHs or OSA or OSAS):ti,ab
#5.	(obes* near/3 hypoventil*):ti,ab
#6.	pickwick*:ti,ab
#7.	(OR #1-#6)
#8.	(sleep* near/3 (tool* or index* or indic* or score* or scoring or scale*)):ti,ab
#9.	((spouse* or wife or wives or husband* or significant other* or partner* or family or families or care giver* or caregiver* or carer* or symptom*) near/1 (report* or observ* or watch* or note* or noting or hear* or listen*)):ti,ab
#10.	(out of hours or off hours):ti,ab
#11.	MeSH descriptor: [Oximetry] explode all trees
#12.	MeSH descriptor: [Capnography] this term only
#13.	MeSH descriptor: [Polysomnography] this term only
#14.	(oximetry or capnogra* or capnometer or polysomnograph* or colorimetr* or conductometr* or potentiometr*):ti,ab
#15.	((carbon dioxide or CO2 or oxygen or O2) near/2 (monitor* or continuous*)):ti,ab
#16.	(blood gas near/2 (monitor* or continuous or test*)):ti,ab

#17.	Epworth Sleepiness Scale:ti,ab
#18.	Apnoea Hypopnea Index:ti,ab
#19.	Oxygen desaturation index:ti,ab
#20.	Calgary Sleep Apnea Quality of Life Index:ti,ab
#21.	(ESS or AHI or ODI or SQALI or ABG):ti,ab
#22.	(OR #8-#21)
#23.	#7 and #22

1 **Epistemonikos search terms**

1.	((title:((sleep apnea syndromes) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (disorder* OR breath*)) OR (OSAHS OR OSA OR OSAS) OR (obes* AND hypoventil*) OR pickwick*) OR abstract:((sleep apnea syndromes) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (apn?ea* OR hypopn?ea*)) OR (sleep* AND (disorder* OR breath*)) OR (OSAHS OR OSA OR OSAS) OR (obes* AND hypoventil*) OR pickwick*)))
----	---

2 **B.2 Health Economics literature search strategy**

3 Health economic evidence was identified by conducting a broad search relating to sleep
4 apnoea population in NHS Economic Evaluation Database (NHS EED – this ceased to be
5 updated after March 2015) and the Health Technology Assessment database (HTA – this
6 ceased to be updated after March 2018) with no date restrictions. NHS EED and HTA
7 databases are hosted by the Centre for Research and Dissemination (CRD). Additional
8 searches were run on Medline and Embase for health economics and quality of life studies.

9 **B.2.1 Health economic studies strategy**

10 **Table 5: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline	2014 – 6 July 2020	Exclusions Health economics studies
Embase	2014 – 6 July 2020	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 31 March 2018 NHSEED - Inception to March 2015	None

11 **Medline (Ovid) search terms**

	exp Sleep Apnea Syndromes/
1.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
2.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
3.	(OSAHS or OSA or OSAS).ti,ab.
4.	(obes* adj3 hypoventil*).ti,ab.
5.	pickwick*.ti,ab.
6.	or/1-6
7.	limit 7 to English language

8.	letter/
9.	editorial/
10.	news/
11.	exp historical article/
12.	Anecdotes as Topic/
13.	comment/
14.	case report/
15.	(letter or comment*).ti.
16.	or/9-16
17.	randomized controlled trial/ or random*.ti,ab.
18.	17 not 18
19.	animals/ not humans/
20.	exp Animals, Laboratory/
21.	exp Animal Experimentation/
22.	exp Models, Animal/
23.	exp Rodentia/
24.	(rat or rats or mouse or mice).ti.
25.	or/19-25
26.	8 not 26
27.	Economics/
28.	Value of life/
29.	exp "Costs and Cost Analysis"/
30.	exp Economics, Hospital/
31.	exp Economics, Medical/
32.	Economics, Nursing/
33.	Economics, Pharmaceutical/
34.	exp "Fees and Charges"/
35.	exp Budgets/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/28-43
44.	27 and 44

1

Embase (Ovid) search terms

1.	exp Sleep Disordered Breathing/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHs or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.

6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter.pt. or letter/
10.	note.pt.
11.	editorial.pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.
14.	or/9-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/
20.	exp Experimental Animal/
21.	animal model/
22.	exp Rodent/
23.	(rat or rats or mouse or mice).ti.
24.	or/16-23
25.	8 not 24
26.	health economics/
27.	exp economic evaluation/
28.	exp health care cost/
29.	exp fee/
30.	budget/
31.	funding/
32.	budget*.ti,ab.
33.	cost*.ti.
34.	(economic* or pharmaco?economic*).ti.
35.	(price* or pricing*).ti,ab.
36.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
37.	(financ* or fee or fees).ti,ab.
38.	(value adj2 (money or monetary)).ti,ab.
39.	or/26-38
40.	25 and 39

1

NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Sleep Apnea Syndromes EXPLODE ALL TREES
#2.	(sleep* adj4 (apn?ea* or hypopn?ea*))
#3.	(sleep* adj4 disorder* adj4 breath*)
#4.	(OSAHS or OSA or OSAS)
#5.	(obes* adj3 hypoventil*)
#6.	(pickwick*)

#7.	#1 OR #2 OR #3 OR #4 OR #5 OR #6
-----	----------------------------------

1 B.2.2 Quality of life studies strategy

2 **Table 6: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline	1946 – 26 November 2019	Exclusions Quality of life studies
Embase	1974 – 26 November 2019	Exclusions Quality of life studies

3 **Medline (Ovid) search terms**

1.	exp Sleep Apnea Syndromes/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHs or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter/
10.	editorial/
11.	news/
12.	exp historical article/
13.	Anecdotes as Topic/
14.	comment/
15.	case report/
16.	(letter or comment*).ti.
17.	or/9-16
18.	randomized controlled trial/ or random*.ti,ab.
19.	17 not 18
20.	animals/ not humans/
21.	exp Animals, Laboratory/
22.	exp Animal Experimentation/
23.	exp Models, Animal/
24.	exp Rodentia/
25.	(rat or rats or mouse or mice).ti.
26.	or/19-25
27.	8 not 26
28.	quality-adjusted life years/
29.	sickness impact profile/
30.	(quality adj2 (wellbeing or well being)).ti,ab.
31.	sickness impact profile.ti,ab.

32.	disability adjusted life.ti,ab.
33.	(qal* or qtime* or qwb* or daly*).ti,ab.
34.	(euroqol* or eq5d* or eq 5*).ti,ab.
35.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
36.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
37.	(hui or hui1 or hui2 or hui3).ti,ab.
38.	(health* year* equivalent* or hye or hyes).ti,ab.
39.	discrete choice*.ti,ab.
40.	rosser.ti,ab.
41.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
42.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
43.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
44.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
45.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
46.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
47.	or/28-46
48.	27 and 47

1

Embase (Ovid) search terms


1.	exp Sleep Disordered Breathing/
2.	(sleep* adj4 (apn?ea* or hypopn?ea*)).ti,ab.
3.	(sleep* adj4 disorder* adj4 breath*).ti,ab.
4.	(OSAHs or OSA or OSAS).ti,ab.
5.	(obes* adj3 hypoventil*).ti,ab.
6.	pickwick*.ti,ab.
7.	or/1-6
8.	limit 7 to English language
9.	letter.pt. or letter/
10.	note.pt.
11.	editorial.pt.
12.	case report/ or case study/
13.	(letter or comment*).ti.
14.	or/9-13
15.	randomized controlled trial/ or random*.ti,ab.
16.	14 not 15
17.	animal/ not human/
18.	nonhuman/
19.	exp Animal Experiment/
20.	exp Experimental Animal/
21.	animal model/
22.	exp Rodent/
23.	(rat or rats or mouse or mice).ti.
24.	or/16-23

25.	8 not 24
26.	quality adjusted life year/
27.	"quality of life index"/
28.	short form 12/ or short form 20/ or short form 36/ or short form 8/
29.	sickness impact profile/
30.	(quality adj2 (wellbeing or well being)).ti,ab.
31.	sickness impact profile.ti,ab.
32.	disability adjusted life.ti,ab.
33.	(qal* or qtime* or qwb* or daly*).ti,ab.
34.	(euroqol* or eq5d* or eq 5*).ti,ab.
35.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
36.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
37.	(hui or hui1 or hui2 or hui3).ti,ab.
38.	(health* year* equivalent* or hye or hyes).ti,ab.
39.	discrete choice*.ti,ab.
40.	rosser.ti,ab.
41.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
42.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
43.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
44.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
45.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
46.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
47.	or/26-46
48.	25 and 47

1

Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of demonstration of efficacy



2

3

1
2
3
4
5
6
7
8
9
10

Appendix D: Clinical evidence tables

No studies included in the review.

Appendix E: Forest Plots

No studies included in the review.


Appendix F: GRADE tables

No studies included in the review.

1
2
3
4
5
6

Appendix G: Health economic evidence selection

Figure 2: Flow chart of health economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language
** Two studies (in three papers) were included for two different questions
*** One study was considered for two different questions

Appendix H: Excluded studies

H.1 Excluded clinical studies

Table 7: Studies excluded from the clinical review

Study	Exclusion reason
Ahmed 2010 ¹	Literature review
Alvarez 2017 ²	Inappropriate intervention- study assessed reliability and accuracy of automated scoring of respiratory events provided by a home non-invasive ventilation device and of manual scoring using available flow and pressure traces obtained from these devices as compared with the results obtained by manual polygraphy scoring.
Arya 2014 ³	Inappropriate intervention- study evaluated patient's post-treatment subjective perception of the effectiveness of CPAP and mandibular advancement devices.
Baessler 2013 ⁴	Inappropriate intervention- study aimed to assess if treatment for sleep apnoea by CPAP will affect levels of inflammatory markers.
Baltaxe 2020 ⁵	Inappropriate population- people with chronic respiratory failure.
Berg 2020 ⁶	Inappropriate intervention- Friedman score. The study investigated the association between Friedman tongue position score (Friedman score) and CPAP or MAS compliance and AHI improvement in patients with non-severe OSA.
Bergeron 2018 ⁷	Inappropriate population – children
Budhiraja 2017 ⁹	Inappropriate intervention and comparison- CPAP vs no CPAP.
Brostrom 2018 ⁸	Validation of two questionnaires to measure shared decision-making during CPAP initiation.
Caminero 1997 ¹⁰	Not in English
Carrera 1998 ¹¹	Study aimed to evaluate the impact upon the therapeutic decision of the definition of hypopnoea most commonly used in different labs, which is a reduction in airflow of 50% or more, accompanied by decrease of blood oxygen saturation of 4%
Choi 2016 ¹²	Inappropriate intervention- the purpose of the meta-analysis was to identify predictors of success after Uvulopalatopharyngoplasty.
Choi 2000 ¹³	Inappropriate intervention-study looked at 10 different derivatives of all night oximeter tracings in patients with OSA and compared their ability to predict the improvement in subjective sleepiness after 6 months of nCPAP therapy.
Choi 2001 ¹⁴	Inappropriate intervention- study aimed to assess changes in nasal continuous positive airway pressure (nCPAP) pressure requirements across time in OSA, and whether routine re titrations are indicated.

Study	Exclusion reason
Damiani 2013 ¹⁵	Inappropriate intervention-study compared titration effectiveness of two auto CPAP devices using different flow-based algorithms in patients with OSA.
Deng 2017 ¹⁶	Not in English
Ebben 2017 ¹⁷	Inappropriate intervention- the goal of the study was to develop new predictive models of CPAP that take into account the style of mask interface.
Georges 2013 ¹⁸	Conference abstract
Georges 2015 ¹⁹	Inappropriate intervention – study assessed validity and accuracy of AHI provided by home ventilators vs data scored manually during polysomnography in subjects on non-invasive ventilation for OHS.
Inoue 2016 ²⁰	Study aimed to examine the relationship between subjective and objective sleepiness and to determine whether baseline objective sleepiness severity predicts the response to modafinil treatment for residual sleepiness in obstructive sleep apnoea syndrome patients.
Javaheri, 2020 ²¹	CPAP vs sham CPAP. To be considered for inclusion in CPAP in mild review.
Jonas 2017 ²²	Inappropriate intervention- screening for obstructive sleep apnoea in adults
Kunisaki 2016 ²³	Systematic review screened for relevant references.
Lee 2013 ²⁴	Inappropriate intervention- the study aimed to develop an equation for optimal CPAP pressure based on data from Asian patients.
Leger 2016 ²⁵	Inappropriate intervention- study evaluated the effectiveness of a novel device NOWAPI designed to assess compliance remotely in conjunction with any CPAP machine.
Masa 2011 ²⁶	Inappropriate population- patients with suspected intermediate or high sleep apnoea and hypopnea syndrome.
Masa 2016 ²⁷	Inappropriate intervention- the objective of the study was to assess the medium-term treatment efficacy of adding supplemental oxygen therapy to commonly prescribed treatment modalities in OHS.
Masa 2013 ²⁸	Inappropriate population- patients with suspected OSA. Inappropriate intervention- home respiratory polygraphy vs polygraphy for diagnosis and treatment
Masa 2019 ²⁹	Inappropriate intervention. Study included in CPAP in OHS review.
Masdeu 2010 ³⁰	Study examined agreement among multiple sleep clinicians when presented with clinical data plus the full tracings and data obtained from unattended limited monitoring or full polysomnography.
McArdle 2015 ³¹	Inappropriate intervention-study assessed the efficacy of female specific auto-titrating continuous positive airway pressure (CPAP)

Study	Exclusion reason
	algorithm in pre-menopausal women relative to a standard auto titrating algorithm.
Mulgrew 2007 ³²	Inappropriate intervention- conventional polysomnography vs ambulatory algorithm for titration of CPAP in patients with a high probability of moderate to severe OSA.
Nannapaneni 2014 ³³	Retrospective chart review of OSA patients on PAP. The review evaluated the clinical utility of annual face to face follow-up visits in this group.
Ng 2019 ³⁵	Inappropriate intervention- study aimed to evaluate the accuracy of the Berlin questionnaire in patients with suspected OSAS
Papadakis 2018 ³⁶	Inappropriate population- children with snoring and tonsillar hypertrophy (4-10 years old)
Patout 2019 ³⁷	Inappropriate intervention and comparison- study compared the physiological effectiveness of non-invasive ventilation set-up guided by polysomnography to limited respiratory monitoring and nurse-led titration in patients with COPD-obstructive sleep apnoea overlap.
Pilz 2000 ³⁸	Inappropriate intervention- CPAP vs auto CPAP
Quintas-Neves 2016 ³⁹	Systematic review aimed to assess and characterise the impact that different types of bariatric surgery have on obese OSA patients.
Rodrigues Thuler 2002 ⁴⁰	Not in English
Rosen 2012 ⁴¹	Inappropriate intervention- home based portable monitoring and auto CPAP vs gold standard lab based polysomnography and CPAP titration for diagnosis and treatment of OSA.
Rosen 2015 ⁴²	Inappropriate population - 5 to 9 year old habitually snoring children. Inappropriate intervention- adenotonsillectomy.
Sanchez-Quiroga 2018 ⁴³	Inappropriate population-patients with suspected OSA. Inappropriate intervention- primary care physician's vs in lab specialised management.
Saur 2017 ⁴⁴	Systematic review – screened for relevant references.
Schobel 2018 ⁴⁵	Study aimed to investigate whether Peripheral arterial tonometry might be a useful tool to improve diagnostic work-up in OSA patients by better identifying residual sleep-disordered breathing due to insufficient CPAP-adjustment.
Suen 2019 ⁴⁶	Narrative review
Sutherland 2014 ⁴⁷	Inappropriate intervention- study aimed to assess the relationship between therapeutic CPAP pressure and mandibular advancement splints treatment response in treatment naive OSA patients.

Study	Exclusion reason
Suzuki 2008 ⁴⁸	Inappropriate intervention- the study evaluated the need for post-operative monitoring of oesophageal pressure in adult OSAHS patients who undergo tonsillectomy with UPPP.
Tam 2014 ⁴⁹	Systematic review investigating the utility of outcome measures other than AHI for patients with OSA undergoing surgery.
Tedeschi 2013 ⁵⁰	Inappropriate population- patients with high suspicion of OSA. Inappropriate intervention- home unattended portable monitoring and auto CPAP vs attended in lab program
Trikalinos 2007 ⁵¹	Not relevant intervention – technology assessment programme (USA) document on home diagnosis of obstructive sleep apnoea-hypopnoea syndrome.

1 H.2 Excluded health economic studies

2 Published health economic studies that met the inclusion criteria (relevant population,
3 comparators, economic study design, published 2003 or later and not from non-OECD
4 country or USA) but that were excluded following appraisal of applicability and
5 methodological quality are listed below:

6 None.

7

8

9

10